You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Chemistry
Bioconjugation
Conjugation methods are crucial for the successful construction of an ADC. It can influence the drug-to-antibody ratio (DAR), stability, PK, therapeutic index, as well as other properties.
- Conventional cysteine conjugation: reduction of interchain disulfides followed by conjugation to electrophilic linker payloads (e.g., maleimide, haloacetyl)
- Site-specific cysteine conjugation: deprotection of mutant cysteine followed by conjugation to linker payloads
- Lysine conjugation: conjugation to lysine residues via activated ester-containing linker payloadÂ
Learn more about